Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Zymeworks Inc (NY: ZYME )

N/A UNCHANGED
Last Price Updated: 7:00 PM EST, Dec 15, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Zymeworks Inc

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
2 Biotech Stocks That Could Make You Richer
These biotech companies are seeing a spike in revenue growth. 
Via The Motley Fool
Why These 7 Stocks Are the Best Ways to Play Biotech Right Now
With biotech stocks offering myriad viable opportunities irrespective of broader conditions, this sector is worth a closer look. 
Via InvestorPlace
Zymeworks Announces Participation in Upcoming Investor Conference
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Appoints New Director
From Zymeworks Inc.
Via GlobeNewswire
7 Analysts Have This to Say About Zymeworks
Via Benzinga
5 Value Stocks In The Healthcare Sector
Via Benzinga
What 6 Analyst Ratings Have To Say About Zymeworks
Via Benzinga
Overview Of Value Stocks In The Healthcare Sector
Via Benzinga
Zymeworks Set to Join Russell 3000®, Russell 2000®, and Russell Microcap® Indexes
From Zymeworks Inc.
Via GlobeNewswire
Over $27M Bet On Zymeworks? Check Out These 3 Stocks Insiders Are Buying
Although US stocks closed lower on Wednesday, there were a few notable insider trades. 
Via Benzinga
The 3 Most Undervalued Growth Stocks for Your June Buy List
Sometimes you can get the best of both worlds in the equities sector, which should draw interest for these undervalued growth stocks. 
Via InvestorPlace
3 Cheap Growth Stocks That Are Too Good to Pass Up
These top bargain growth stocks are all priced under $10 a share and offer real upside potential for investors. 
Via InvestorPlace
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
What 7 Analyst Ratings Have To Say About Zymeworks
Via Benzinga
Daiichi, Zymeworks Terminate Seven Year-Cancer Antibody Pact
Via Benzinga
Zymeworks Announces Departure of Neil Klompas, President and Chief Operating Officer
From Zymeworks Inc.
Via GlobeNewswire
Top 5 Health Care Stocks That May Collapse In Q2
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
Zymeworks Provides Corporate Update and Reports First Quarter 2023 Financial Results
From Zymeworks Inc.
Via GlobeNewswire
Earnings Scheduled For May 8, 2023
Companies Reporting Before The Bell • HNI (NYSE:HNI) is likely to report quarterly loss at $0.03 per share on revenue of $462.26 million. 
Via Benzinga
Analyst Ratings for Zymeworks
Via Benzinga
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Presents New Data from Multiple Preclinical and Clinical Development Programs at the 2023 American Association for Cancer Research Annual Meeting
From Zymeworks Inc.
Via GlobeNewswire
The 7 Most Undervalued Stocks You Need to Know About
Given the risks targeting highly popular trades right now, the most undervalued stocks to buy may offer greater mileage. 
Via InvestorPlace
Zymeworks To Host First Quarter 2023 Results Conference Call
From Zymeworks Inc.
Via Business Wire
Zymeworks Announces Appointment of Derek J. Miller to its Board of Directors
From Zymeworks Inc.
Via Business Wire
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via Business Wire
Zymeworks to Present Updated Data on Multiple Product Candidates at the American Association for Cancer Research (AACR) Annual Meeting
From Zymeworks Inc.
Via Business Wire
Zymeworks Offers Hope for More than Just Long-Term Investors
Zymeworks stock is up nearly 5% since reporting earnings and a rally that has put ZYME stock over 25% in the last 12 months and could send the stock higher 
Via MarketBeat
Why Rigel Pharmaceuticals Shares Are Trading Higher By Over 30%; Here Are 20 Stocks Moving Premarket
Gainers Fresh Tracks Therapeutics, Inc. (NASDAQ: FRTX) rose 51.1% to $2.66 in pre-market trading after the company disclosed topline results from single and multiple ascending dose parts of Phase 1... 
Via Benzinga
Zymeworks Reports Fourth Quarter and Full Year 2022 Financial Results
From Zymeworks Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.